Phytomedicine : international journal of phytotherapy and phytopharmacology · 2026
Flavonoid GL-V9 as a novel and potent acetyl-coa carboxylase 1 inhibitor confers cisplatin hypersensitivity in ovarian cancer.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jiang Zihao, Cai Yelin, Zhu Jiawei, Lu Zeyuan, Wang Cong, Huang Bao-Sheng, Guo Qinglong, Zhang Hongchuan, Chen Guo, Guo Yongjian
Аннотация
BACKGROUND: Cisplatin has been a cornerstone of Ovarian cancer (OC) treatment since its clinical introduction in the 1970s, with platinum-based regimens forming the core of first-line therapy. However, approximately 70% of patients eventually experience disease recurrence and develop resistance to platinum. To date, few clinically viable alternatives to cisplatin have emerged for the effective management of OC.
PURPOSE: Therefore, this study aims to identify a novel agent capable of enhancing cisplatin sensitivity and overcoming chemoresistance in ovarian cancer.
STUDY DESIGN: This study evaluates the anti-tumor effects of GL-V9 in ovarian cancer, elucidates its underlying mechanisms, and evaluates its potential for clinical translation.
METHODS: The mechanisms underlying the effects of GL-V9 were investigated using streptavidin pull-down assays, functional analyses (cell viability, clonogenic survival, and apoptosis), and Western blotting. The antitumor efficacy of GL-V9 alone and in combination with cisplatin was further evaluated in an A2780 ovarian cancer xenograft model.
RESULTS: We found that GL-V9, a flavonoid derived from Scutellaria, exerted potent antitumor effects in OC by inducing apoptosis and inhibiting proliferation. Furthermore, GL-V9 enhanced cisplatin sensitivity and reversed cisplatin resistance. Mechanistically, GL-V9 directly bound to and inhibited acetyl-CoA carboxylase 1 (ACC1), leading to elevated intracellular reactive oxygen species (ROS) levels. Both in vitro and in vivo experiments confirmed that GL-V9, alone or in combination with cisplatin, significantly suppressed tumor growth without observable toxicity.
CONCLUSION: GL-V9 overcomes cisplatin resistance in ovarian cancer by targeting ACC1 and elevating ROS levels, highlighting its potential as a clinically translatable therapeutic strategy.
PURPOSE: Therefore, this study aims to identify a novel agent capable of enhancing cisplatin sensitivity and overcoming chemoresistance in ovarian cancer.
STUDY DESIGN: This study evaluates the anti-tumor effects of GL-V9 in ovarian cancer, elucidates its underlying mechanisms, and evaluates its potential for clinical translation.
METHODS: The mechanisms underlying the effects of GL-V9 were investigated using streptavidin pull-down assays, functional analyses (cell viability, clonogenic survival, and apoptosis), and Western blotting. The antitumor efficacy of GL-V9 alone and in combination with cisplatin was further evaluated in an A2780 ovarian cancer xenograft model.
RESULTS: We found that GL-V9, a flavonoid derived from Scutellaria, exerted potent antitumor effects in OC by inducing apoptosis and inhibiting proliferation. Furthermore, GL-V9 enhanced cisplatin sensitivity and reversed cisplatin resistance. Mechanistically, GL-V9 directly bound to and inhibited acetyl-CoA carboxylase 1 (ACC1), leading to elevated intracellular reactive oxygen species (ROS) levels. Both in vitro and in vivo experiments confirmed that GL-V9, alone or in combination with cisplatin, significantly suppressed tumor growth without observable toxicity.
CONCLUSION: GL-V9 overcomes cisplatin resistance in ovarian cancer by targeting ACC1 and elevating ROS levels, highlighting its potential as a clinically translatable therapeutic strategy.